文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

地拉罗司减轻MDS骨髓细胞氧化DNA损伤并改善分化能力

Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
PubMed 文献 · Br J Haematol · 2019-06-06

研究纳入13例铁过载的低危MDS患者,比较地拉罗司治疗前与治疗后4-10个月的骨髓细胞。结果显示MDS骨髓细胞活性氧和DNA氧化损伤高于健康供者,地拉罗司治疗后DNA氧化损伤下降,集落形成试验提示分化能力改善,集落/CFU比值降至接近对照水平。

要点

  • 低危MDS铁过载患者骨髓细胞活性氧和DNA氧化损伤高于健康供者。
  • 地拉罗司治疗后骨髓细胞DNA氧化损伤下降。
  • 地拉罗司似乎改善造血分化能力,集落/CFU比值降至接近对照。

核心结论

  • MDS骨髓细胞处于较高氧化应激状态且造血分化受损,地拉罗司治疗后这些不良特征似乎部分得到纠正。

研究设计与样本

  • 分析13例铁过载MDS患者地拉罗司治疗前及治疗后4-10个月的骨髓样本,并与健康供者比较。

主要发现

  • 与健康供者相比,MDS患者骨髓细胞内活性氧水平和DNA氧化损伤更高。
  • 地拉罗司治疗后DNA氧化损伤下降。
  • 治疗前集落形成试验提示造血分化受损,治疗后集落/CFU比值下降并达到与对照相似的水平。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with low-risk myelodysplastic syndromes (MDS) usually develop iron overload. This leads to a high level of oxidative stress in the bone marrow (BM) and increases haematopoietic cell dysfunction. Our objective was to analyse whether chelation with deferasirox (DFX) alleviates the consequences of oxidative stress and improves BM cell functionality. We analysed 13 iron-overloaded MDS patients' samples before and 4-10 months after treatment with DFX. Using multiparametric flow cytometry analysis, we measured intracellular reactive oxygen species (ROS), DNA oxidation and double strand breaks. Haematopoietic differentiation capacity was analysed by colony-forming unit (CFU) assays. Compared to healthy donors, MDS showed a higher level of intracellular ROS and DNA oxidative damage in BM cells. DNA oxidative damage decreased following DFX treatment. Furthermore, the clonogenic assays carried out before treatment suggest an impaired haematopoietic differentiation. DFX seems to improve this capacity, as illustrated by a decreased cluster/CFU ratio, which reached values similar to controls. We conclude that BM cells from MDS are subject to higher oxidative stress conditions and show an impaired haematopoietic differentiation. These adverse features seem to be partially rectified after DFX treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jiménez-Solas T, López-Cadenas F, Aires-Mejía I, et al. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity. Br J Haematol. 2019. PMID: 31172513. doi:10.1111/bjh.16013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。